Drugs targeting the orthosteric, primary binding site of G protein-coupled receptors are the most common therapeutics. Allosteric binding sites, elsewhere on the receptors, are less well-defined, and so less exploited clinically. We report the crystal structure of the prototypic b 2 -adrenergic receptor in complex with an orthosteric agonist and compound-6FA, a positive allosteric modulator of this receptor. It binds on the receptor's inner surface in a pocket created by intracellular loop 2 and transmembrane segments 3 and 4, stabilizing the loop in an a-helical conformation required to engage the G protein.
G protein-coupled receptors (GPCRs) regulate virtually all physiological processes in humans and are the subjects of intense drug discovery efforts (1, 2) . Recent structures of GPCRs bound to allosteric modulators have revealed that receptor surfaces are decorated with diverse cavities and crevices that may serve as allosteric modulatory sites (3) . This substantiates the notion that GPCRs are structurally plastic and can be modulated by a variety of allosteric ligands through distinct mechanisms (4) (5) (6) (7) (8) (9) . Most of these structures have been solved with negative allosteric modulators (NAMs), which stabilize receptors in their inactive states (3) . To date, only a single structure of an active GPCR bound to a small-molecule positive allosteric modulator (PAM) has been reported, namely, the M 2 muscarinic acetylcholine receptor with LY2119620 (10) . Thus, mechanisms of PAMs and their potential binding sites remain largely unexplored.
The b 2 -adrenergic receptor (b 2 AR), a prototypic class A GPCR, plays essential roles in cardiovascular and respiratory physiology and is the therapeutic target of clinical drugs such as betablockers and beta-agonists (11) . We previously reported a cell-permeable NAM of the b 2 AR, compound-15 (Cmpd-15), which binds to a cytoplasmic pocket within the central helical core of the receptor and prevents structural rearrangements necessary for receptor activation (12, 13) . We recently identified compound-6 (Cmpd-6), a positive allosteric modulator of the b 2 AR, through affinity-based screening with DNA-encoded smallmolecule libraries against purified agonist-bound b 2 AR (14) .
exhibits robust positive cooperativity with orthosteric agonists and transducers (b-arrestins and G proteins), and potentiates agonist-induced adenosine-3′,5′-cyclic monophosphate production and b-arrestin recruitment to the b 2 AR (14) . Furthermore, Cmpd-6 is negatively cooperative with Cmpd-15 ( fig. S1A ) and reduces antagonist binding to the b 2 AR (fig. S1B). To both visualize the interaction of Cmpd-6 with the b 2 AR and to understand the mechanism behind its positive allostery, we sought to obtain a crystal structure of the active receptor in complex with Cmpd-6.
The active state of the b 2 AR is conformationally unstable, and the addition of a G protein or a G protein mimetic is required for capturing this state by crystallography (15) (16) (17) (18) . We used nanobody 6B9 (Nb6B9) to stabilize the active state of b 2 AR, as Cmpd-6 does not interfere with the ability of Nb6B9 to bind to agonist-occupied b 2 AR and enhance agonist affinity (fig. S1, C and D). To facilitate crystallogenesis, we used a previously described amino-terminal T4 lysozymeb 2 AR (T4L-b 2 AR) fusion protein (19) . Cmpd-6 maintains its ability to enhance agonist binding of the T4L-b 2 AR (fig. S1E ).
We initially crystallized the T4L-b 2 AR bound to the agonist BI-167107, and Nb6B9, with 30 mM Cmpd-6 (solubility limit) in the crystallization solution. However, we were not able to identify electron density representing Cmpd-6. This was attributed to Cmpd-6's micromolar affinity and poor solubility. To improve solubility, we synthesized a derivative of Cmpd-6 (Cmpd-6FA) having a free carboxylic acid group (acetic acid) at its terminal amide site previously used for conjugating its DNA tag (Fig. 1A) . Cmpd-6FA has approximately sixfold higher solubility in aqueous solutions and recapitulates the pharmacological properties of the parent compound in in vitro assays with purified b 2 AR (Fig. 1B) . To assess the direct molecular interaction between Cmpd-6FA and wild-type b 2 AR, we performed isothermal titration calorimetry (ITC) in the presence of BI-167107. The interaction is exothermic and enthalpically favorable with a stoichiometry of 1 and dissociation constant (K D ) of 1.2 mM (Fig. 1C) . When tested using b 2 AR bound to the antagonist carazolol, ITC detected no measurable physical interaction between the receptor and Cmpd-6FA, consistent with its role as a PAM ( fig. S2 ). Like the parent Cmpd-6, Cmpd-6FA displays positive cooperativity with the stimulatory G protein (G s ) and b-arrestin1 (barr) ( fig. S3) (14) .
We obtained crystals of the active T4L-b 2 AR bound to BI-167107 and Nb6B9 in a crystallization condition saturated with 3 mM Cmpd-6FA. The complex structure was resolved to 3.2 Å by the molecular replacement method using the T4L-b 2 AR-Nb6B9 structure (17) as the search model (table S1). Clear electron density was observed for Cmpd-6FA and was localized at the interface between the cytoplasm and membrane (Fig. 1, D and E, and fig. S4 ). However, the simulated annealing omit map was relatively weak, and a contour level of 2s was required to see the shape of Cmpd-6FA ( fig. S4A ). We therefore generated a polder map, which excludes bulk solvent around the ligand (see materials and methods) and provides better density for the compound (fig .  S4C ). The Cmpd-6FA that we used in crystallographic work is a mixture of two enantiomers with N1 as chiral center. An S configuration at nitrogen N1 was docked in our model on the basis of the density, but owing to the limitation of the crystal resolution, we cannot exclude the possibility that the R enantiomer is the correct one. The newly identified allosteric binding site is formed by the transmembrane (TM) helices 2, 3, 4, and intracellular loop (ICL) 2 (Fig. 1E) . Notably, this site was not previously predicted to be a druggable allosteric site for the b 2 AR (20); therefore, its identification not only improves our understanding of the druggable molecular landscape on the b 2 AR but also expands our concept of what surface features can constitute an allosteric site.
The majority of the contacts at the binding interface between Cmpd-6FA and the b 2 AR are mediated by hydrophobic and van der Waals interactions, which is consistent with the hydrophobic nature of the compound ( fig. S5 ). Cmpd-6FA can be subdivided into four chemical groups: core scaffold, N-methylpropan-2-amine (R1), 4-methoxybenzene (R2), and tert-butylbenzene (R3) (Fig. 1A) . The R1, R2, and R3 chemical moieties interact with three surface features of the b 2 AR -the cytoplasmic, membrane-proximal, and membraneembedded surfaces ( Fig. 2A) . The core scaffold spans both the membrane-proximal and cytoplasmic surfaces and provides a central point for the R1, R2, and R3 groups to extend into their respective binding surface features.
The core scaffold of Cmpd-6FA forms a hydrogen bond with Lys149 4.41 (the only hydrogen bond between the compound and b 2 AR) and van der Waals contacts with Phe133 3.52 and Leu144 ICL2 (Fig. 2B) . The acetate group of Cmpd-6FA, which was chemically added to enhance the compound solubility, makes minimal contacts with the b 2 AR and points toward solvent in the crystal structure. The R1, R2, and R3 moieties provide the majority of interactions with the protein surface (Fig. 2C) .
To understand the structural basis of PAM activity, we compared our structure of the active b 2 AR-Cmpd-6FA occupied by the agonist BI-167107 to the structure of the inactive b 2 AR occupied by the antagonist carazolol (21) . A superposition of these models reveals structural changes associated with receptor activation consistent with previous crystallographic studies of the b 2 AR (16, 18) , such as the reorganization of ICL2 from a random coil to a two-turn a helix (Fig. 3A) . Tyr141
ICL2 is positioned to both form a hydrogen bond with Asp130 3.49 of the conserved (DRY) motif in TM3 and stabilize the a-helical conformation of ICL2 within the active structure. Conversely, Tyr141
ICL2 is situated nearly 12 Å away from the aspartate residue in the inactive structure. As a result of these structural changes, particularly in ICL2, the topography of the Cmpd-6FA binding site is particular to the active state of the b 2 AR (Fig. 3B) . The a-helical conformation of the ICL2 favors G protein binding because Phe139 adopts an orientation suitable to interact with a hydrophobic pocket on Ga s (Fig. 3, A and C) .
The stabilization of the ICL2 a helix by Cmpd-6FA may explain its ability to enhance agonist affinity (Fig. 1B) . The formation of the two-turn a helix in ICL2 requires an inward displacement of Pro138
ICL2
. This displacement results in a~3-Å inward movement of TM3, which in turn dictates an outward movement of TM5 and TM6 to prevent steric clashes between Tyr132 3.51 and Ile135 3.54 and residues on TM5 and TM6 (Fig. 3D ). This outward movement of TM5 and TM6 is a hallmark of GPCR activation. In this way, Cmpd-6FA binding increases the population of receptors adopting active conformations, which have higher affinity for agonists (16) (17) (18) 22) . Conversely, the structural rearrangements that are required when ICL2 forms an a helix would be disfavored when the receptor is bound to an orthosteric inverse agonist, explaining the observation that Cmpd-6FA does not bind to carazolol-bound b 2 AR (fig.  S2 ). Further, Cmpd-6 retards agonist dissociation ( fig. S1F ) and exerts its "agonist trapping" effect (23) not through direct steric occlusion but rather through stabilizing the active state of the receptor with a closed hormone-binding site. This mode of action differs from the mechanism previously reported for the PAM that targets the M 2 muscarinic acetylcholine receptor, whereby the allosteric modulator binds within the extracellular vestibule to directly prevent agonist dissociation (10) .
To determine if Cmpd-6FA stabilizes a distinct conformation in the b 2 AR, we superimposed the b 2 AR-BI-167107-Nb6B9-Cmpd-6FA structure with the previously reported b 2 AR-BI-167107-Nb6B9 structure (17) . Although the superposition showed the overall conformation of the receptors and agonist interactions to be nearly identical (root mean square deviation 0.37 Å, fig. S6A ), there are local conformational differences at the Cmpd-6FA binding site ( fig. S6B ). In particular, the side chains of Phe133 3.52 and Tyr141 ICL2 of the b 2 AR bound to Cmpd-6FA are pivoted to provide optimal shape complementarity with the allosteric ligand.
To validate our crystal structure, we performed a structure-activity relationship study using a set of Cmpd-6 derivatives. Figure S7 summarizes the allosteric effects of these analogs on agonist binding affinity for the b 2 AR. The reduced function of the analogs agrees well with the Cmpd-6FA interactions observed in the crystal structure.
Allosteric sites may not face the same evolutionary pressure as do orthosteric sites, and thus are more divergent across subtypes within a receptor family (24) (25) (26) . Therefore, allosteric sites may provide a greater source of specificity for targeting GPCRs. Cmpd-6 is much more efficacious in enhancing agonist binding and receptor-mediated signaling for the human b 2 AR, compared to the closely related b 1 AR subtype (Fig. 4) . Sequence alignment of the b 2 AR and b 1 AR reveals that only 7 out of the 14 amino acid residues that form the Cmpd-6FA allosteric site are conserved (Fig. 4A) . To investigate the roles of the seven different residues, we constructed a series of b 1 AR mutants matching these residues to their counterparts in the b 2 AR. Subsequently, we performed [
125 I]cyanopindolol (CYP) competition binding assays with these mutants in the presence or absence of Cmpd-6. Consistent with previous studies, Cmpd-6 enhances the agonist ISO binding affinity of the b 2 AR by 31-fold (Fig. 4B) and has only marginal effect toward the b 1 AR (2.8-fold increase, Fig. 4C ). When all seven residues of the b 1 AR were mutated to match their counterparts in the b 2 AR, agonist affinity was enhanced by 13-fold in the presence of Cmpd-6 (Fig. 4D) . We speculated that the mutations at Leu158 3.52 and Arg174 4.41 may be the major determinants of the observed gain of function with the b 1 AR, as their b 2 AR counterparts play important roles in binding to the core scaffold of Cmpd-6FA binding (Fig. 2, B and C, and fig. S8, A  and B) . Indeed, the single mutations of Leu158 A and B), and the b 1 AR containing both of the Leu158 3.52 Phe and Arg174 4.41 Lys mutations conferred a 20-fold shift (Fig. 4E) . It is interesting that the Arg174 4.41 Lys mutation has such a pronounced effect given that they are both basic amino acids. However, the structure reveals that the bulkier side chain of an arginine would not fit into the space between ICL2 and Cmpd-6FA ( fig. S8C ). Taken together, these gain-of-function studies are in accordance with the crystal structure of b 2 AR-Cmpd-6FA and strongly support the proposed allosteric site and binding mode of Cmpd-6FA.
Recently, the crystal structure of the free fatty acid receptor GPR40 in complex with its partial agonist MK-8666 and allosteric agonist AP8 was reported (27) . Although the complex represents the inactive state of the receptor, it reveals the binding site of AP8, which is located outside the seven-transmembrane helical bundle at a lipid-facing region formed by TM helices 3, 4, and 5 ( fig. S10A ). An overlay of this structure and our b 2 AR structure bound to Cmpd-6FA shows that AP8 partially extends into the membraneembedded surface and overlaps with the R2 moiety of Cmpd-6FA ( fig. S10B ). More recently, mutagenesis and chimeric receptor studies suggested that the binding site for DETQ, a PAM for the dopamine D1 receptor, is located near ICL2, although no structural data were presented (28).
Thus, this general locale in class A GPCRs can exert positive allostery and may be exploited for therapeutic purposes.
We have identified a binding pocket on the b 2 AR that engages Cmpd-6FA, which is positioned on the surface of the helical bundle at the interface of the cytoplasm and membrane. Through structure-activity relationship studies and gain-of-function mutagenesis on the closely related b 1 AR subtype, we validated the binding site of Cmpd-6FA. Comparing the structure of the b 2 AR bound to Cmpd-6FA with the active and inactive receptors provided a mechanistic understanding of the positive allosteric modulatory effects of Cmpd-6FA. These structural comparisons suggest that Cmpd-6FA enhances both orthosteric agonist binding and transducer coupling by stabilizing the active state of the b 2 AR. 
